{
    "clinical_study": {
        "@rank": "127790", 
        "arm_group": [
            {
                "arm_group_label": "GLP=2", 
                "arm_group_type": "Experimental", 
                "description": "active treatment with a single dose of GLP-2 (1500mcg)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "1. To assess whether Glucagon like peptide 2 (GLP-2) affects lipoprotein production (study\n           A)\n\n        2. To assess whether GLP-2 affects the release of preformed chylomicrons (study B)"
        }, 
        "brief_title": "Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dyslipidemia", 
        "condition_browse": {
            "mesh_term": "Dyslipidemias"
        }, 
        "detailed_description": {
            "textblock": "Study A: Using constant feeding with a nasoduodenal tube and stable isotope infusion,\n      mathematical modelling will be utilised to measure lipoprotein production and clearance. The\n      lipoproteins assessed will be apoB-100 from the liver and apoB-48 from the intestine.\n\n      StudyB: Volunteers will be given a liquid meal with retinyl palmitate (vitamin A) to label\n      chylomicrons made from the meal. 7 hours later they will be given GLP-2 or placebo.\n      Measurements of plasma and TRL(triglyceride rich lipoprotein) triglyceride and TRL retinyl\n      palmitate will be carried out to see whether GLP-2 increases these parameters."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Inclusion Criteria:\n\n               1. Men and women, aged 18 to 60 years\n\n               2. Body mass index 20 kg/m2 to 30 kg/m2\n\n               3. Hemoglobin above 130g/L.\n\n               4. Normal glucose tolerance in response to a 75g, 2-hr oral glucose tolerance test\n                  (OGTT)\n\n        Exclusion Criteria:\n\n          -  1. Subject has a history of hepatitis/hepatic disease that has been active within the\n             previous two years.\n\n             2. Any significant active (over the past 12 months) disease of the gastrointestinal,\n             pulmonary, neurological, renal (Cr > 1.5 mg/dL), genitourinary, hematological\n             systems, or has severe uncontrolled treated or untreated hypertension (sitting\n             diastolic BP > 100 or systolic > 180) or proliferative retinopathy 3. History of\n             diabetes or OGTT indicative of diabetes or impaired glucose tolerance.\n\n             4. Any history of ischemic heart disease or clinically significant, active,\n             cardiovascular history including a history of arrhythmia's or conduction delays on\n             ECG, unstable angina, or decompensated heart failure.\n\n             5. Abnormal liver or thyroid function tests 6. Current addiction to alcohol or\n             substances of abuse as determined by the investigator.\n\n             7. Mental incapacity, unwillingness or language barrier precluding adequate\n             understanding or cooperation 8. Taking any prescription or non-prescription\n             medications at the time of the study 9. Having donated blood three months prior to\n             and three months post study procedures 10. A pregnancy test will be performed 1 to 3\n             days prior to each study in all female research participants. Those who test positive\n             for pregnancy will be excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01958775", 
            "org_study_id": "REB-07-0394"
        }, 
        "intervention": [
            {
                "arm_group_label": "GLP=2", 
                "description": "single subcutaneous dose of 1500mcg", 
                "intervention_name": "GLP-2", 
                "intervention_type": "Drug", 
                "other_name": "glucagon like peptide 2"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glucagon", 
                "Glucagon-Like Peptide 1"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Lipoproteins, apoB, GLP-2", 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5G 1L7"
                }, 
                "name": "Toronto General Hospital"
            }, 
            "investigator": {
                "last_name": "Gary Lewis, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like", 
        "overall_contact": {
            "email": "brenda.hughes@uhn.ca", 
            "last_name": "Brenda Hughes, RN", 
            "phone": "416-340-4000", 
            "phone_ext": "8886"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ApoB 100 and ApoB 48 production and clearance", 
            "measure": "Lipoprotein production and clearance rate", 
            "safety_issue": "No", 
            "time_frame": "10 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01958775"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measurements will be carried out hourly after ingestion of meal and then every 15-30 minutes thereafter to see if GLP-2 increases these parameters compared to placebo.", 
            "measure": "Plasma and TRL triglyceride and TRL retinyl palmitate", 
            "safety_issue": "No", 
            "time_frame": "10 hours"
        }, 
        "source": "University Health Network, Toronto", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Health Network, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}